:,,

Matthew Collin1

  • 1Institute of Translational and Clinical Research, Newcastle University, Newcastle upon Tyne, UK.

PubMed
概括

BRAF和MEK抑制剂为高风险的质细胞瘤提供了新的希望. 然而,这篇评论质疑是否完全响应允许针对性治疗中止.